Intra-Cellular Therapies' GAAP loss for 6M 2021 was $121.484 million, up 9.3% from $111.123 million in the prior year. Revenue increased 12-fold to $35.925 million from $2.99 million a year earlier.
Warning BlackTerminal uses cookies in order to personalize and improve the usability of the service. If you do not want to use cookies, please change your browser settings. Accept